- Kreu
- /
- Listim Brandesh
- /
- Respiratory System
{loadposition position-9}
{loadposition position-7}
List of reimbursed drugs, is an important part of Service Packages covering the Fund of Compulsory Health Care Insurances for the population. The list of reimbursable drugs aims at improving the quality of service for all patients, particularly for people in need. In this regard, through the new list of drugs, FCHC aims at increasing the attention toward categories such as retirees and patients suffering from serious illnesses.
In compiling the list of drugs there are some scientific criteria which have been taken into consideration, by giving priority to drugs used for severe diseases; diseases of high risk for life; diseases that cause disability; diseases that risk of being spread into the society; diseases that cause much suffering as well as chronic illnesses requiring prolonged treatment.
Respiratory System - Reimbursed
Sugar coated tablets - 50 mg
Mebhydrolin is a substance that is part of the group of antihistamines. The antihistamines reduce or inhibit the main actions of histamine in the organism through the reversible and competitive block of the histamine receptors; they do not disactivate histamine or do not prevent its synthesis or release. Mebhidroline presents antimuscarinic, serotonine antagonist properties and local anaesthetic effects. It is used for the symptomatic relief of hypersensitivity reactions, including urticaria and angioedema, rhinitis and conjunctivitis. It is considered as ineffective in asthma.
Mebhidroline sugar-coated tablet 50 mg is indicated in:
Chewable tablets - 5 mg
Film coated tablets - 10 mg
Syrup - 250 mg / 5 ml
Syrup - 100 mg / 5 ml
Solution for injection - 50 mg / 2 ml
Promethazine is a phenothiazine derivative, which decreases or eliminates the main histamine actions by competing with histamine or reversibly blocking histamine receptors in tissues. Promethazine does not deactivate histamine, and does not prevent its secretion. H1 receptors are responsible for blood vessel dilation, increase of capillary permeability, itching and, up to an extent, for bronchial and gastrointestinal tract smooth muscle contractions. Promethazine has also antimuscarinic properties, antagonizing effects of adrenaline and serotonin and local anesthetic effects.
Prometazine 50 mg / 2 ml solution for injection is indicated:
By intramuscular injection:
By intravenous injection:
as an adjuvant agent in anaesthesia and analgesia in order to reduce the dose of pethidine or other narcotic analgesics, especially in several specific surgical procedures (for example: repeated bronchoscopy, surgical ophthalmologic intervention).
Sugar coated tablets - 25 mg
Promethazine is a phenothiazine derivative, which decreases or eliminates the main histamine actions by competing with histamine or reversibly blocking histamine receptors in tissues. Promethazine does not deactivate histamine, and does not prevent its secretion. H1 receptors are responsible for blood vessel dilation, increase of capillary permeability, itching and, up to an extent, for bronchial and gastrointestinal tract smooth muscle contractions. Promethazine has also antimuscarinic properties, antagonizing effects of adrenaline and serotonin and local anesthetic effects.
Prometazine 25 mg sugar-coated tablets are indicated in:
Nasal spray solution - 0.5 mg / ml
Nasal spray solution - 0.25 mg / ml
Nasal drops, solution - 0.9 %
Syrup - (0.6 mg + 0.08 mg + 40 mg + 90 mg ) / 1 g
Syrup - (0.6 mg + 0.08 mg + 40 mg + 90 mg ) / 1 g
